Cambridge Cognition Launches Aqua Automated Quality Assurance Solution
Mixture to be used for central nervous system clinical trials.
Cambridge Cognition announced that it has officially launched Aqua, its automated quality assurance solution for central nervous system (CNS) clinical trials. Powered by the company’s winterlight speech and language platform, the solution is the first product of its kind to be available on the market.
“Aqua is an entirely new solution for the clinical trials market providing a level of quality assurance that was not possible before, from a cost or time perspective, with traditional reviews by medical experts,” said Matthew Stork, CEO, Cambridge Cognition. “We acquired Winterlight Labs intending to commercialize their innovative verbal clinical assessments and, by launching Aqua, we have achieved the first of our product goals. We are also really pleased to have already won a client for Aqua as we expect this will provide us with an excellent case study for future sales.”
Reference: Launch of automated quality assurance for clinical trials. Cambridge Cognition. October 24, 2023. Accessed October 25, 2023. https://cambridgecognition.com/launch-of-automated-quality-assurance-for-clinical-trials/
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025